A company focused on discovering, developing and commercializing treatments for diabetes and cancer – MannKind Corporation (Nasdaq: MNKD) – has recently received USFDA clearance for its Investigational New Drug (IND) application for MKC1106-PP Immunotherapy in Solid Malignancies.
The said IND clearance serves a go signal for MannKind to proceed with the initiation of its Phase 1 clinical trial – a multicenter, open label, clinical trial of immune response, safety and tolerability of a DNA vector with two synthetic peptides in subjects with solid malignancies, in a plasmid prime-peptide boost treatment.
The clinical study is designed to target two tumor-specific antigens, preferential antigen of melanoma (PRAME) and prostate specific membrane antigen (PSMA), on the basis of their level of expression in commonly occurring adult malignancies, such as ovarian, prostate, renal, pancreatic, breast, colon carcinoma and melanoma.Find more details from the press release.
.jpg)
Comment Preview